Skip to main content

Table 2 Summary of Pre-Treatment Disease Characteristics and Outcome Measures

From: Efficacy, tolerability, and safety of erenumab for the preventive treatment of persistent post-traumatic headache attributed to mild traumatic brain injury: an open-label study

 Persistent PTH (n = 89)
Disease Characteristics during 28-day Pre-Treatment Phase
 Headache days of any severity, mean (SD)24.6 ± 6.1
 Headache days of moderate to severe intensity, mean (SD)15.7 ± 9.6
 Days with use of any acute headache medication, mean (SD)4.0 ± 4.4
 HIT-6 score, mean (SD)61.6 ± 5.2
Primary Outcome Measure
 Mean change in number of monthly headache days of moderate to severe intensity from baseline to week 9–12 (SD)−2.8 (6.8)
Secondary Outcome Measures
 Mean change in number of monthly headache days of any intensity from baseline to week 9–12 (SD)−1.7 (6.9)
  ≥ 25% reduction in mean monthly headache days of any intensity, baseline to week 12, %21
  ≥ 50% reduction in mean monthly headache days of any intensity, baseline to week 12, %13
  ≥ 75% reduction in mean monthly headache days of any intensity, baseline to week 12, %6
 Mean change in HIT-6 score from baseline to week 12 (SD)−4.6 (7.3)
Post-Hoc Explorative Outcome Measures
  ≥ 25% reduction in mean monthly headache days of moderate to severe intensity, baseline to week 12, %47
  ≥ 50% reduction in mean monthly headache days of moderate to severe intensity, baseline to week 12, %28
  ≥ 75% reduction in mean monthly headache days of moderate to severe intensity, baseline to week 12, %13
 Mean change in number of monthly days using acute headache medications, baseline to week 9–12 (SD)−0.4 (5.2)
\